RemeGen Co., Ltd. (OTCMKTS:REGMF) Short Interest Up 32,700.0% in March

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a significant growth in short interest in March. As of March 13th, there was short interest totaling 328,000 shares, a growth of 32,700.0% from the February 26th total of 1,000 shares. Based on an average daily trading volume, of 304 shares, the short-interest ratio is presently 1,078.9 days. Based on an average daily trading volume, of 304 shares, the short-interest ratio is presently 1,078.9 days.

RemeGen Stock Performance

RemeGen stock remained flat at $10.00 during mid-day trading on Tuesday. The company’s fifty day moving average price is $10.13 and its 200 day moving average price is $9.94. RemeGen has a fifty-two week low of $9.81 and a fifty-two week high of $15.91.

RemeGen Company Profile

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.